Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
Combining a diabetes drug with a gel-forming polymer could mean less frequent injections for people with the disease.
Diabetes drugs that mimic a signalling molecule called glucagon-like peptide-1 (GLP1) can control blood glucose levels, but they are short-lived in the body and have to be injected weekly. To make a GLP1 drug that lasts longer, Ashutosh Chilkoti at Duke University in Durham, North Carolina, and his colleagues fused GLP1 to a protein called ELP, which can be made to form a gel at specific temperatures.